Cargando…

The Effect of Iron and Erythropoietin Treatment on the A1C of Patients With Diabetes and Chronic Kidney Disease

OBJECTIVE: To examine the effect of intravenous iron and erythropoietin-stimulating agents (ESAs) on glycemic control and A1C of patients with diabetes and chronic kidney disease (CKD). RESEARCH DESIGN AND METHODS: This was a prospective study of patients with type 2 diabetes and CKD stage IIIB or I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ng, Jen M., Cooke, Michelle, Bhandari, Sunil, Atkin, Stephen L., Kilpatrick, Eric S.
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2010
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2963485/ https://www.ncbi.nlm.nih.gov/pubmed/20798337 http://dx.doi.org/10.2337/dc10-0917

Ejemplares similares

Safety of intravenous iron use in chronic kidney disease
por: Kalra, Philip A., et al.
Publicado: (2016)

Effect of intravenous iron on endogenous erythropoietin and FGF-23 secretion in patients with chronic kidney disease
por: Muras-Szwedziak, Katarzyna, et al.
Publicado: (2023)

A1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes: Data from the Diabetes Control and Complications Trial
por: Kilpatrick, Eric S., et al.
Publicado: (2008)

The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans
por: Bielesz, Bernhard, et al.
Publicado: (2020)

Disparate Effects of Atorvastatin Compared With Simvastatin on C-Reactive Protein Concentrations in Patients With Type 2 Diabetes
por: Sathyapalan, Thozhukat, et al.
Publicado: (2010)

Impact of Intravenous Iron on Oxidative Stress and Mitochondrial Function in Experimental Chronic Kidney Disease
por: Nuhu, Faisal, et al.
Publicado: (2019)

Does erythropoietin slow progression of chronic kidney disease?
por: Nasri, Hamid, et al.
Publicado: (2013)

Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin
por: Hanna, Ramy M., et al.
Publicado: (2020)

Treatment of Anemia in Kidney Disease: Beyond Erythropoietin
por: Wish, Jay B.
Publicado: (2021)

Analysis of oxidative stress, inflammation and endothelial function following intravenous iron in chronic kidney disease in the Iron and Heart Trial
por: Kassianides, Xenophon, et al.
Publicado: (2022)

The comparative effects of intravenous iron on oxidative stress and inflammation in patients with chronic kidney disease and iron deficiency: a randomized controlled pilot study
por: Kassianides, Xenophon, et al.
Publicado: (2021)

Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD)
por: Ziedan, Ahmed, et al.
Publicado: (2019)

The Impact of Intravenous Iron on Renal Injury and Function Markers in Patients With Chronic Kidney Disease and Iron Deficiency Without Anemia
por: Kassianides, Xenophon, et al.
Publicado: (2021)

Patient reported outcome measures and cardiovascular outcomes following high dose modern intravenous iron in non-dialysis dependent chronic kidney disease: secondary analysis of ExplorIRON-CKD
por: Kassianides, Xenophon, et al.
Publicado: (2023)

Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
por: Hayat, Amir, et al.
Publicado: (2008)

Erythropoietin Resistance in Patients with Chronic Kidney Disease: Current Perspectives
por: Santos, Elton Jonh Freitas, et al.
Publicado: (2020)

Lower serum prohepcidin levels associated with lower iron and erythropoietin requirements in hemodialysis patients with chronic hepatitis C
por: Caliskan, Yasar, et al.
Publicado: (2012)

Correction to: Protocol and baseline data for a prospective open-label explorative randomized singlecenter comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD)
por: Ziedan, Ahmed, et al.
Publicado: (2020)

The Role of Blood Pressure Variability in the Development of Nephropathy in Type 1 Diabetes
por: Kilpatrick, Eric S., et al.
Publicado: (2010)

Management of anaemia in CKD—the relative importance of erythropoietin and iron
por: Agarwal, Rajiv
Publicado: (2011)

Evaluating Preoperative Intravenous Iron and Erythropoietin Treatment and Outcomes in Cardiac Surgery Patients
por: Jahangirifard, Alireza, et al.
Publicado: (2023)

Effect of Glucose Variability on the Long-Term Risk of Microvascular Complications in Type 1 Diabetes
por: Kilpatrick, Eric S., et al.
Publicado: (2009)

Erythropoietin (EPO) in acute kidney injury
por: Moore, Elizabeth, et al.
Publicado: (2011)

Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor
por: Khalil, Shadi, et al.
Publicado: (2018)

Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor
por: Oshima, Megumi, et al.
Publicado: (2020)

A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia
por: Kalra, Philip A., et al.
Publicado: (2016)

Effect of Maintenance Intravenous Iron Treatment on Erythropoietin Dose in Chronic Hemodialysis Patients: A Multicenter Randomized Controlled Trial
por: Susantitaphong, Paweena, et al.
Publicado: (2020)

Assessment of Erythropoietin Levels and Some Iron Indices in Chronic Renal Failure and Liver Cirrhosis Patients
por: Mady, Essam, et al.
Publicado: (1999)

Interpretation of Erythropoietin and Haemoglobin Levels in Patients with Various Stages of Chronic Kidney Disease
por: Panjeta, Mirsad, et al.
Publicado: (2017)

The Biological Variation of N-Terminal Pro-Brain Natriuretic Peptide in Postmenopausal Women with Type 2 Diabetes: A Case Control Study
por: González, Susana, et al.
Publicado: (2012)

Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial
por: Bhandari, Sunil, et al.
Publicado: (2020)

NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease
por: Kalra, Philip A., et al.
Publicado: (2020)

Predictors of iron versus erythropoietin responsiveness in anemic hemodialysis patients
por: Hildebrand, Sarah, et al.
Publicado: (2022)

Markers of Oxidative Stress, Inflammation and Endothelial Function following High-Dose Intravenous Iron in Patients with Non-Dialysis-Dependent Chronic Kidney Disease—A Pooled Analysis
por: Kassianides, Xenophon, et al.
Publicado: (2022)

Factors Governing the Erythropoietic Response to Intravenous Iron Infusion in Patients with Chronic Kidney Disease: A Retrospective Cohort Study
por: Chukwu, Chukwuma A., et al.
Publicado: (2023)

Comparison of efficacy of roxadustat and erythropoietin for the treatment of renal anemia in patients with chronic kidney disease: a retrospective study
por: Jin, Chen, et al.
Publicado: (2022)

Precision Medicine in Erythropoietin Deficiency and Treatment Resistance: A Novel Approach to Management of Anaemia in Chronic Kidney Disease
por: Yugavathy, Nava, et al.
Publicado: (2023)

Renal Cell Protection of Erythropoietin beyond Correcting The Anemia in Chronic Kidney Disease Patients
por: Nasri, Hamid
Publicado: (2014)

Impaired erythropoietin synthesis in chronic kidney disease is caused by alterations in extracellular matrix composition
por: Olmos, Gemma, et al.
Publicado: (2017)

Efficacy & safety of continuous erythropoietin receptor activator (CERA) in treating renal anaemia in diabetic patients with chronic kidney disease not on dialysis
por: Vankar, Sameer G., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mlu4f30nuvj234afulobc1krgf